SCHEMBL2481971

SCHEMBL2481971

Cc1n[nH]c(=S)o1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419664 0.65
SCHEMBL14140127 0.54
SCHEMBL12020221 0.43
SCHEMBL28031735 0.42
SCHEMBL5080529 0.39
SCHEMBL2998374 0.39
SCHEMBL37498 0.39
SCHEMBL1549115 0.39
SCHEMBL735951 0.39
SCHEMBL11219157 0.36

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228472-A1 HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2024-07-11 US disclosed
WO-2022005961-A1 PRPK INHIBITORS DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-01-06 WO disclosed
US-10737280-B2 Method of using flotation collector containing azolethione structure CENTRAL SOUTH UNIVERSITY (CN) 2020-08-11 US disclosed
EP-3081213-B1 TRICYCLIC COMPOUND KYOWA KIRIN CO LTD (JP) 2020-04-01 EP disclosed
US-20190217310-A1 METHOD OF USING FLOTATION COLLECTOR CONTAINING AZOLETHIONE STRUCTURE CENTRAL SOUTH UNIVERSITY (CN) 2019-07-18 US disclosed
US-20190038588-A1 NOVEL CLASS OF COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE STICHTING KATHOLIEKE UNIVERSITEIT (NL) 2019-02-07 US disclosed
US-9956302-B2 Compounds and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2018-05-01 US disclosed
US-20180110864-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2018-04-26 US disclosed
US-20180110864-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2018-04-26 US disclosed
US-20180104350-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2018-04-19 US disclosed
EP-1944305-A1 Quinoline derivatives as phosphodiesterase inhibitors GLAXO GROUP LIMITED (GB) 2008-07-16 EP disclosed
US-20080058347-A1 Novel aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2008-03-06 US disclosed
WO-2008026768-A1 NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION BANYU PHARMACEUTICAL CO., LTD (JP) 2008-03-06 WO disclosed
US-20080058347-A1 Novel aminopyridine derivatives having aurora a selective inhibitory action MSD K.K. (JP) 2008-03-06 US disclosed
EP-1633748-B1 QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS GLAXO GROUP LTD (GB) 2008-03-05 EP disclosed
US-20070259874-A1 Phosphodiesterase Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2007-11-08 US disclosed
US-20070259874-A1 Phosphodiesterase Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2007-11-08 US disclosed
WO-2007123936-A1 NOVEL HETEROARYL-SUBSTITUTED ARYLAMINOPYRIDINE DERIVATIVES AS MEK INHIBITORS LABORATOIRES SERONO SA (CH) 2007-11-01 WO disclosed
EP-1687292-B1 VITAMIN D RECEPTOR MODULATORS LILLY CO ELI (US) 2007-08-22 EP disclosed
WO-2005051931-A2 PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-06-09 WO disclosed